<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefuroxime: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefuroxime: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefuroxime: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11920" href="/d/html/11920.html" rel="external">see "Cefuroxime: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13137" href="/d/html/13137.html" rel="external">see "Cefuroxime: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866263"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Cefuroxime;</li>
<li>Auro-Cefuroxime;</li>
<li>Ceftin;</li>
<li>PRO-Cefuroxime-500 [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F148353"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F148308"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> IM is an FDA-approved route and can be given at the same dose as IV.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use):</b>
<b>Oral:</b> 500 mg twice daily, in combination with an agent appropriate for anaerobes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2021b','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2021b','lexi-content-ref-24947530'])">Ref</a></span>). Duration of prophylaxis is 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>). Duration of treatment for established infection typically ranges from 5 to 14 days and varies based on clinical response and patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2021a','lexi-content-ref-Baddour.2021b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation: Note:</b> Avoid use in patients with risk factors for <i>Pseudomonas</i> infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Sethi.1','lexi-content-ref-23874094','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Sethi.1','lexi-content-ref-23874094','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV:</b> 1.5 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>). <b>Note: </b>The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, appendicitis, diverticulitis, intra-abdominal abscess): </i>
<b>IV:</b> 1.5 g every 8 hours in combination with metronidazole. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Erythema migrans:</i>
<b>Oral:</b> 500 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carditis (initial therapy for mild disease [first-degree atrioventricular block with PR interval &lt;300 msec] or step-down therapy after initial parenteral treatment for more severe disease once PR interval &lt;300 msec): </i>
<b>Oral:</b> 500 mg twice daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Arthritis without neurologic involvement (alternative agent) (off-label use):</i>
<b>Oral:</b> 500 mg twice daily for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hu.1','lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hu.1','lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (initial therapy for mild infection or step-down therapy after parenteral treatment) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients unable to take penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg twice daily in combination with metronidazole; continue until clinical resolution, typically for 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent for mild [nonanaphylactic] penicillin allergy) (off-label):</b>
<b>Oral:</b> 500 mg twice daily; duration of therapy is 5 to 7 days (mild to moderate infection) <b>or</b> 10 days (severe infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Limb.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Limb.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae7a1cf7-80fc-4d1d-9ece-3f02289932d6">Pneumonia, community-acquired, outpatient empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, outpatient empiric therapy (patients with comorbidities):</b>
<b>Oral:</b> 500 mg twice daily as part of an appropriate combination regimen. Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs before discontinuing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044','lexi-content-ref-Pichichero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044','lexi-content-ref-Pichichero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 mg twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17908614','lexi-content-ref-Pichichero.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17908614','lexi-content-ref-Pichichero.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (eg, cardiac surgery, head and neck surgery) (alternative agent):</b>
<b>IV:</b> 1.5 g within 60 minutes prior to surgical incision; use in combination with metronidazole for select head and neck procedures. Cefuroxime dose may be repeated intraoperatively in 4 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799638','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799638','lexi-content-ref-23327981'])">Ref</a></span>). Postoperative prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c28df2f-628a-4b10-8f0b-f480126b47a9">Urinary tract infection, cystitis, acute uncomplicated or acute simple cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use only when first-line agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.1','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-Hooton.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991631"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Cefuroxime Dose Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">IV</p></th>
<th align="center">
<p style="text-indent:0em;">Oral</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 750 mg to 1.5 g every 8 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 250 to 500 mg every 12 hours</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Expert opinion derived from concentrations observed in Konishi 1993.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≥30</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to 30</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg to 1.5 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 12 hours (preferred)<sup>a</sup> or 250 to 500 mg every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg to 1.5 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 24 hours (preferred)<sup>a</sup> or 250 to 500 mg every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Extended infusion: 1.5 g infused over 3 hours every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24917580','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24917580','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: 1.5 g loading dose, followed by 6 g infused over 24 hours every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24917580','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24917580','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (enhances plasma clearance by at least 30% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.1'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for patients with CrCl &lt;10 mL/minute; when scheduled dose falls on a dialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20919394','lexi-content-ref-20919391','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20919394','lexi-content-ref-20919391','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> Dose as for patients with CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4047273','lexi-content-ref-20919391','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4047273','lexi-content-ref-20919391','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27494946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27494946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988919"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doe drugH1Div" id="F148309"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F148329"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13137" href="/d/html/13137.html" rel="external">see "Cefuroxime: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, IM: 100 to 150 mg/kg/day in divided doses every 8 hours; maximum daily dose: 6,000 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 20 to 30 mg/kg/day in divided doses every 12 hours; maximum daily dose: 1,000 mg/<b>day</b>; higher doses may be used for some indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1701ac17-544f-4206-a37e-0462fd6cd656">Chronic bronchitis, acute bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, acute bacterial exacerbation:</b> Adolescents: Oral: 250 to 500 mg every 12 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day in divided doses every 6 to 8 hours as part of an appropriate combination regimen; maximum dose: 1,500 mg/dose. Treatment duration varies based on specific source of infection, success of source control procedures, and clinical response; a total duration of 5 to 7 days following source control is typically recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (</b>
<i>
<b>Borrelia </b></i>
<b>spp. infection):</b> Infants, Children, and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours; maximum dose: 500 mg/dose. Duration of therapy depends on clinical syndrome; treat erythema migrans and borrelial lymphocytoma for 14 days, carditis for 14 to 21 days, arthritis (initial, recurrent, or refractory) for 28 days, and acrodermatitis chronica atrophicans for 21 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5285a396-852e-4b3d-b4b0-d754f216f7be">Osteoarticular infection, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection, acute (eg, septic [bacterial] arthritis, osteomyelitis):</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV, IM: Infants ≥3 months, Children, and Adolescents: IV, IM: 150 to 200 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 6,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-29290233','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-29290233','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Limited data available: Infants ≥3 months, Children, and Adolescents: Oral: 60 to 100 mg/kg/day in divided doses every 8 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35763692','lexi-content-ref-28708801','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35763692','lexi-content-ref-28708801','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration of therapy: Minimum total duration (IV plus oral therapy) is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration should be individualized based on several factors including causative pathogen, response to therapy, and normalization of inflammatory markers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-34350458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-34350458'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (AOM) (alternative agent for nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8192458','lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8192458','lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>). For patients with severe or recurrent AOM, tympanic membrane perforation, or who are &lt;2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, nonrecurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f897d5-d979-4ccb-be61-83112266c583">Pneumonia, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, bacterial (alternative agent):</b> Infants and Children: HIV-exposed/-infected: IV: 105 to 150 mg/kg/day in divided doses every 8 hours; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b> Infants ≥3 months, Children, and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours for 10 days; maximum dose: 500 mg/dose. Manufacturer labeling suggests that children and adolescents may also receive 250 mg in oral tablets every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-manu.1'])">Ref</a></span>). Limited data exist to determine optimal duration; historically 10 days has been recommended, but recently some have suggested a duration as short as 5 days; some patients may require extended therapy (ie, 14 to 21 days) based on clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23796742','lexi-content-ref-Bradley.2','lexi-content-ref-22438350','lexi-content-ref-NICE.2','lexi-content-ref-34118486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23796742','lexi-content-ref-Bradley.2','lexi-content-ref-22438350','lexi-content-ref-NICE.2','lexi-content-ref-34118486'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (SSTI) (including impetigo):</b>
<b>Note:</b> Alternative agents are preferred for first-line treatment of SSTI (eg, first-generation cephalosporins) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Infants ≥3 months, Children, and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12182257','lexi-content-ref-1416842','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12182257','lexi-content-ref-1416842','lexi-content-ref-manu.1'])">Ref</a></span>). For impetigo, treat for 7 days; typical duration for other uncomplicated skin and soft tissue infection is 5 days, but therapy may be extended if clinical response is inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30777258','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30777258','lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants ≥3 months and Children ≤11 years: IV: 50 to 100 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 1,500 mg/dose. Transition to oral therapy when able; total duration dependent on presentation, severity of infection, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10440436','lexi-content-ref-30777258','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10440436','lexi-content-ref-30777258','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy): </b>
<b>Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broad-spectrum cephalosporins such as cefuroxime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: Oral: 20 mg/kg/day in divided doses every 12 hours for 10 days; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044','lexi-content-ref-15084807','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044','lexi-content-ref-15084807','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 mg/kg within 60 minutes prior to incision; may repeat dose in 4 hours if procedure is lengthy or if there is excessive blood loss; maximum dose: 1,500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Infants, Children, and Adolescents: Limited data available in ages ≤12 years: Oral: 20 to 30 mg/kg/day in divided doses every 12 hours; maximum daily dose: 1,000 mg/day. European guidelines suggest that this dose may be administered in divided doses every 8 hours. Manufacturer labeling suggests that adolescents with uncomplicated infection may receive 250 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-25477258','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-29292282','lexi-content-ref-25477258','lexi-content-ref-manu.1'])">Ref</a></span>). Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; typical duration is 7 to 14 days, though it may be as short as 3 to 5 days (eg, for uncomplicated cystitis in patients ≥2 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258','lexi-content-ref-33589366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258','lexi-content-ref-33589366'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084389"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note: </b>For oral therapy, there are no dosage adjustments provided in the manufacturer's labeling; for IV therapy, the manufacturer recommends similar adjustments to those provided for adults. However, the following guidance has been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Cefuroxime Dosage Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>GFR</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>IV</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Oral</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2"></td>
<td align="left">
<p style="text-indent:0em;">If usual recommended dose is 75 to 150 mg/kg/<b>day</b> divided every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">If usual recommended dose is 30 mg/kg/<b>day</b> divided every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Usual dose: 25 to 50 mg/kg/dose every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Usual dose: 15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 to 29 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;10 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Intermittent hemodialysis</p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours; administer after dialysis on dialysis days</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours; administer after dialysis on dialysis days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Peritoneal dialysis (PD)</p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of drug penetration to site of infection, minimal inhibitory concentration (MIC) of bacteria, severity of illness, receipt of any initial loading doses, etc. Due to minimal data, consider monitoring serum concentrations if available.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 25 to 50 mg/kg/<b>dose</b> every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>); intervals of every 12 to 18 hours have also been suggested depending on effluent flow rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14969569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14969569'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51084390"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F148270"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (4% to 11%; duration dependent)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Local thrombophlebitis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaper rash (children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (3% to 7%), unpleasant taste (children: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (≤10%), decreased hemoglobin (≤10%), eosinophilia (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2%), increased serum alkaline phosphatase (2%), increased serum aspartate aminotransferase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Jarisch-Herxheimer reaction (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, chest tightness, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, dyspepsia, flatulence, gastrointestinal infection, oral mucosa ulcer, sialorrhea, stomach cramps, swollen tongue</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, urethral bleeding, urethral pain, urinary tract infection, vaginal discharge, vaginal irritation, vulvovaginal candidiasis, vulvovaginal pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia, positive direct Coombs test</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, drowsiness, drug fever, headache, hyperactive behavior, irritability, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, joint swelling, muscle cramps, muscle rigidity, muscle spasm (neck)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis, <i>Clostridioides difficile</i>-associated diarrhea, <i>Clostridioides difficile</i> colitis, colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, leukopenia, pancytopenia, prolonged prothrombin time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction (may include ischemic heart disease with or without acute myocardial infarction)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal insufficiency</p></div>
<div class="block coi drugH1Div" id="F148286"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefuroxime, any component of the formulation, or other beta-lactam antibacterial drugs (eg, penicillins and cephalosporins)</p></div>
<div class="block war drugH1Div" id="F148267"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy because cross sensitivity among beta-lactam antibacterial drugs has been established. If an allergic reaction occurs, discontinue and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with a history of colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; cephalosporins have been associated with seizure activity, particularly in patients with renal impairment not receiving dose adjustments. Discontinue if seizures occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets: Should not be crushed or chewed due to a strong, persistent bitter taste.</p></div>
<div class="block prod-avail drugH1Div" id="F53145111"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ceftin oral suspension has been discontinued in the US for more than 1 year. </p></div>
<div class="block foc drugH1Div" id="F148279"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as axetil [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F148263"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F148288"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefuroxime Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $2.70 - $3.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefuroxime Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 g (per each): $5.40 - $7.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cefuroxime Axetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $4.39 - $5.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $5.50 - $11.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866264"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg (1 ea); 1.5 g (1 ea); 7.5 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as axetil [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ceftin: 125 mg/5 mL (70 mL, 100 mL) [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as axetil [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ceftin: 250 mg [DSC], 500 mg [DSC] [contains methylparaben, propylparaben, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F148283"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral suspension:</b> Administer with food. Shake well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral tablet:</b> May administer with or without food (absorption improved with food). Swallow tablet whole (crushed tablet has strong, persistent, bitter taste).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject deep IM into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Inject direct IV over 3 to 5 minutes. Infuse intermittent infusion over 15 to 30 minutes.</p></div>
<div class="block admp drugH1Div" id="F52612389"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Cefuroxime axetil suspension must be administered with food; shake suspension well before use; the dose may be added to cold milk, fruit juice, or lemonade prior to administration if desired (Canadian product). Tablets may be administered with or without food; administer with food to increase absorption; avoid crushing the tablet due to its bitter taste.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Inject deep IM into large muscle mass, such as gluteus or lateral part of thigh.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Administer over 15 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer over 3 to 5 minutes.</p></div>
<div class="block use drugH1Div" id="F148282"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone and joint infections (injection only):</b> Treatment of bone and joint infections caused by <i>Staphylococcus aureus</i> (penicillinase- and non-penicillinase-producing strains).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (tablets only): </b> Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in adults and adolescents ≥13 years of age caused by <i>Streptococcus pneumoniae, Haemophilus influenzae </i>(beta-lactamase negative strains), or <i>Haemophilus parainfluenzae</i> (beta-lactamase negative strains).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lower respiratory tract infections (injection only):</b> Treatment of lower respiratory tract infections, including pneumonia, caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (including ampicillin-resistant strains), <i>Klebsiella</i> spp., <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>Streptococcus pyogenes,</i> and <i>Escherichia coli</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (early) (tablets only):</b> Treatment of adults and adolescents ≥13 years of age with early Lyme disease (eg, erythema migrans, carditis) caused by <i>Borrelia burgdorferi</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (tablets and oral suspension only):</b> Treatment of pediatric patients ≥3 months of age with acute bacterial otitis media caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>Moraxella catarrhalis</i> (including beta-lactamase-producing strains), or <i>S. pyogenes.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Septicemia (injection only):</b> Treatment of septicemia caused by <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>S. pneumoniae</i>, <i>E. coli</i>, <i>H. influenzae</i> (including ampicillin-resistant strains), and <i>Klebsiella</i> spp.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sinusitis, acute bacterial (tablets and oral suspension only): </b>Treatment of mild to moderate acute bacterial maxillary sinusitis caused by <i>S. pneumoniae</i> or <i>H. influenzae</i> (non-beta-lactamase-producing strains only).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Effectiveness for sinus infections caused by beta-lactamase-producing <i>H. influenzae</i> or <i>M. catarrhalis</i> in patients with acute bacterial maxillary sinusitis has not been established. <b>Note</b>: According to the IDSA guidelines for acute bacterial rhinosinusitis, cefuroxime is no longer recommended as monotherapy for initial empiric treatment (IDSA [Chow 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin-structure infections (impetigo) (oral suspension only):</b> Treatment of pediatric patients 3 months to 12 years of age with skin or skin-structure infections (impetigo) caused by <i>S. aureus</i> (including beta-lactamase-producing strains) or <i>S. pyogenes</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin-structure infections (injection; tablets [uncomplicated infections only]):</b> Treatment of adults and pediatric patients &gt;3 months of age with skin and skin-structure infections (including impetigo) caused by <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>S. pyogenes</i>, <i>E. coli</i>, <i>Klebsiella</i> spp., and <i>Enterobacter</i> spp.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (tablets and oral suspension only):</b> Treatment of mild to moderate pharyngitis/tonsillitis caused by <i>S. pyogenes</i> in adults and pediatric patients ≥3 months of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Efficacy in the prevention of rheumatic fever has not been established in clinical trials. Efficacy in the treatment of penicillin-resistant strains of <i>S. pyogenes</i> has not been demonstrated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (injection only):</b> Prophylaxis of infection in patients undergoing surgical procedures that are classified as clean-contaminated or potentially contaminated procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (tablets and injection only):</b> Treatment of adults and pediatric patients &gt;3 months of age with urinary tract infection caused by <i>E. coli</i> and <i>Klebsiella</i> spp.</p></div>
<div class="block off-label drugH1Div" id="F28575415"><span class="drugH1">Use: Off-Label: Adult</span><p>Bite wound, prophylaxis or treatment (animal or human bite); Intra-abdominal infection, mild to moderate, community acquired in patients without risk factors for resistance or treatment failure; Lyme disease (Borrelia spp. infection), arthritis without neurologic involvement; Odontogenic soft tissue infection, pyogenic</p></div>
<div class="block mst drugH1Div" id="F148361"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cefuroxime may be confused with cefotaxime, cefprozil, deferoxamine, sulfaSALAzine</p>
<p style="text-indent:-2em;margin-left:4em;">Ceftin may be confused with Cefzil, Cipro</p>
<p style="text-indent:-2em;margin-left:4em;">Zinacef may be confused with Zithromax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ceftin [US, Canada] may be confused with Cefiton brand name for cefixime [Portugal]; Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298999"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F148272"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Cefuroxime. Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the absorption of Cefuroxime.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the absorption of Cefuroxime.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F148300"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Bioavailability is increased with food; cefuroxime serum levels may be increased if taken with food or dairy products. Clinical and bacteriologic responses were independent of food intake in clinical trials. Management: Administer tablet without regard to meals; suspension must be administered with food.</p></div>
<div class="block pri drugH1Div" id="F5193889"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefuroxime crosses the placenta (Dallmann 2017; Lalic-Popovic 2016).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following maternal use of cephalosporin antibiotics, including cefuroxime.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of cefuroxime may be altered (Dallmann 2017; Lalic-Popovic 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Cefuroxime is one of the antibiotics effective for prophylactic use prior to cesarean delivery (ACOG 2018). Cefuroxime is used for the treatment of Lyme disease. Vertical transmission from mother to fetus is not well documented; it is unclear if infection increases the risk of adverse pregnancy outcomes. When treatment for Lyme disease in pregnancy is needed, the indications and dosing of cefuroxime are the same as in nonpregnant patients (IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).</p></div>
<div class="block brc drugH1Div" id="F148289"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of cefuroxime is 0.5% when calculated using the highest breast milk concentration located and compared to an oral infant therapeutic dose of 30 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of cefuroxime was calculated using the highest milk concentration located (1.05 mcg/mL), providing an estimated daily infant dose via breast milk of 0.158 mg/kg/day. This milk concentration was obtained 0.5 to 1.5 hours following maternal administration of oral cefuroxime axetil 500 mg (Vree 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">Diarrhea has been reported in breastfeeding infants exposed to cefuroxime (Benyami 2005). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Beta-lactam antibiotics are generally considered compatible with breastfeeding when used in usual recommended doses; cefuroxime was not specifically included within this report (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F148290"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain phenylalanine and/or sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Should be taken with food. </p></div>
<div class="block mop drugH1Div" id="F148277"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F148266"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F148285"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral tablet: Increases with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to body tissues and fluids including bronchial secretions, synovial and pericardial fluid, kidneys, heart, liver, bone and bile; crosses blood-brain barrier.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and children ≤6 years of age: 0.65 L/kg (del Rio 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 50 ± 28 L (Nix 1997).</p>
<p style="text-indent:-2em;margin-left:4em;">Brain tissue:blood ratio, steady state (AUC): 33% (Hosman 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 33% to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Cefuroxime axetil (oral) is hydrolyzed in the intestinal mucosa and blood to cefuroxime.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: Fasting: 37%; Following food: 52%; Cefuroxime axetil suspension is less bioavailable than the tablet (91% of the AUC for tablets).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤3 days: Median: 5.8 hours (de Louvois 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≥8 days: Median: 1.6 to 3.8 hours (de Louvois 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and adolescents: 1.4 to 1.9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~1 to 2 hours; prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: ~15 to 60 minutes; IV: 2 to 3 minutes; Oral: Children: ~3 to 4 hours; Adults: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (66% to 100% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F54898431"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent, associated with free time (<i>f</i>T) drug concentration &gt; minimum inhibitory concentration (MIC); goal: ≥40%<i> f</i>T &gt; MIC (Craig 1998; Nielsen 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in patients with normal renal function</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and children ≤6 years of age: C<sub>max</sub> (peak): IV, single dose:</p>
<p style="text-indent:-2em;margin-left:8em;">50 mg/kg: 105 ± 36 mg/L (del Rio 1982).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 7 to 12 years of age: C<sub>max </sub>(peak): Oral (tablet), single dose:</p>
<p style="text-indent:-2em;margin-left:8em;">500 mg (fed): 4.3 to 5.7 mg/L (Ginsburg 1985).</p>
<p style="text-indent:-2em;margin-left:8em;">500 mg (fasting): 3.8 to 3.9 mg/L (Ginsburg 1985).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 1.5 g, single dose: 100 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral (tablet), steady state:</p>
<p style="text-indent:-2em;margin-left:10em;">250 mg (fed): 4.1 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg (fed): 7 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg (fasted): 4.9 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i>
<i>H. influenzae</i>: 0 to ~1.4 hours; <i>M. catarrhalis</i>: 0 to ~1.4 hours; <i>S. pneumoniae</i>: ~0.2 to 2.9 hours; <i>S. pyogenes</i>: 0 to ~1.75 hours; <i>S. aureus</i>: Not observed in most isolates (Craig 1993; Davies 2000; Dubois 2000).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F148291"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefovex | Cefutil | Cefuzime | Ceroxim | Cetil | Daroxime | Maxil | Medo axetine | Neoxime | U cef | Zamur | Zenon | Zinacef | Zinnat | Zinoxime | Zinoximor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefurox | Cefuroxima | Cefuroxima klonal | Cefuroxima richet | Deltrox | Fada cefuroxima</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefuroxim | Cefuroxim aptapharma | Cefuroxim astro-pharma gmbh | Cefuroxim hexal pharma | Cefuroxim hikma | Cefuroxim MIP | Cefuroxim sandoz | Cefuroxim Sandoz | Curocef | Furoxim | Ximaract | Zinnat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pharmacor cefuroxime | Zinnat</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Axefur | Axet | Axetil | Axibid | Axicef | Axim | Bactikil | Benkill | Cefobac | Cefore | Cefotil | Cefroxil | Cefstar | Cefuact | Cefusil | Cefuson | Cefuxet | Ceroxime | Cexitil | Famicef | Fixcef | Furex | Furocef | Furotec | Furotil | Furotixol | Fuxtil | Kfore | Kilbac | Kilmax | Lepath | Libotil | Menat | Merocef | Mextil | Orextil | Picocef | Primocef | Probac | Recofast | Rofurox | Roxcef | Roxibac | Roxicil | Roxilab | Roximax | Secomax | Sefur | Sefurox | Sharpkil | Staxim | Til | Turbocef | Uroxime | Vexotil | Winfax | Xefrim | Ximetil | Ximorox | Xinarox | Xitil | Xorimax | Zinacef | Zinatil | Zinnat</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefurim | Cefuroxim fresenius kabi | Cefuroxim krka | Cefuroxim Mylan | Cefuroxim sodium sandoz | Cefuroxime bexal | Cefuroxime EG | Cefuroxime Sandoz | Cefuroxime sandoz | Doc cefuroxim | Doccefuro | Kefurox | Ximaract | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Auroxetil | Cefrotil | Cfr 250 | Kefrox | Rocetil | Uroxime | Zamur | Zinnat</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aksef | Axetine | Cefurocon | Cefuroxim | Cefuroxim abr | Cefuroxim MIP | Cefuroxim Panpharma | Cefuroxim tchaikapharma | Cefuroxime actavis | Furocef | Kefurox | Lifurox | Neofuroxime | Ximaract | Xorimax | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Axetil cefuroxima | Axetilcefuroxima | Cefuroxima sodica | Keroxime | Medcef | Mefex | Zencef | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefurim eco | Cefuroxim actavis | Cefuroxim axapharm | Cefuroxim fresenius | Cefuroxim Labatec | Cefuroxim Mepha | Cefuroxim Sandoz | Cefuroxim spirig | Cefuroxim spirig hc | Cefuroxim Teva | Zinat</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Auroxetil | Cef2 | Ceforix | Cefuaxit | Cefuroxime sp | Cesavess | Cfr 250 | Furoxim | Lodifur | Melrox | Pulmocef | Rocetil | Sefurox | Xorimax | Zinnat | Zocef</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cerevax | Curocef | Favanex | Zinnat</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An ke xin | Axetine | Ba xin | Cefuroxime | Da li xin | Fu le xin | Jia nuo xin | Kai di xin | Kai yi | Ke li di | Ku xin | Li fu xin | Li jian xin | Lifurox | Monacef | Pa wei xin | Pai wei xin | Pu li xin | Pu xin | Qing fu kang | Rui fu xin | Si pei ding | Supero | Xi lu xin | Xin fu xin | Xin lu xin | Ya xing | Yaxing | You le xin | Yun tai | Zinacef</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Binoxim | Cefome | Cefuroxima | Cefuroxima axetil | Cefxiro | Ocumisona | Xorimax | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Axetine | Cefuroxim Kabi | Cefuroxim Pliva | Medoxin | Ricefan | Xorimax | Zinacef | Zinnat | Zinoxime | Znobact</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefudura | Cefuhexal | Cefuro Puren | Cefurox | Cefurox basics | Cefurox basics sun | Cefuroxim | Cefuroxim actavis | Cefuroxim al | Cefuroxim alkem | Cefuroxim aristo | Cefuroxim Aurus | Cefuroxim Axcount | Cefuroxim beta | Cefuroxim CT | Cefuroxim deltaselect | Cefuroxim dr. eberth | Cefuroxim Eberth | Cefuroxim fresenius | Cefuroxim heumann | Cefuroxim hexal | Cefuroxim hikma | Cefuroxim puren | Cefuroxim Ratiopharm | Cefuroxim saar | Cefuroxim sandoz | Cefuroxim Sandoz | Cefuroxim stada | Ceroxim | Elobact | Ximaract | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Cefuromac | Cefuroxima | Ceroxim | Neo erocetin | Zetnil | Zinnat</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Axil | Cefulam | Cefur | Cefurex | Cefurmax | Cefurokron | Cefuroxima | Cefuroxint t | Cefusyn | Cefuzime | Celbix | Ceroxim | Excima | Furacam | Furoxicher | Furoxim | Italfur | Toxedin | Xefurex | Xorimax | Zamur | Zinnat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Cefoprim | Cefuroxim | Cefuroxime | Elobact | Furocef | Keroxime | Ketocef | Xorimax | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefumax | Ceroxim | Hebiuroxime | Oracef | Pancef | Zimocefox | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefuroxima Apotex | Cefuroxima aurobindo | Cefuroxima aurovitas | Cefuroxima Bexal | Cefuroxima chiesi | Cefuroxima Cinfa | Cefuroxima combino | Cefuroxima Davur | Cefuroxima ges | Cefuroxima Ips | Cefuroxima Kern Pharma | Cefuroxima krka | Cefuroxima liderfarm | Cefuroxima mundogen | Cefuroxima normon | Cefuroxima Pensa | Cefuroxima Qualigen | Cefuroxima Ranbaxy | Cefuroxima Ratiopharm | Cefuroxima Reig Jofre | Cefuroxima Sala | Cefuroxima sandoz | Cefuroxima Stada | Cefuroxima stada genericos | Cefuroxima tecnigen | Cefuroxima teva | Curoxima | Lifurox | Nivador | Prokam | Selan | Ximaract | Zanetin | Zinnat</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Auroxetil | Cefuroxime | Cefuroxime synto | Gulf cefuroxime | Sanfur</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefuroxim b. braun | Cefuroxim generics | Cefuroxim MIP pharma | Cefuroxim sandoz | Cefuroxim stragen | Cefuroxime Aurobindo | Cefuroxime orion | Kefurion | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefuroxime Actavis | Cefuroxime Arrow | Cefuroxime bgr | Cefuroxime biogaran | Cefuroxime cristers | Cefuroxime Dci | Cefuroxime flavelab | Cefuroxime kabi | Cefuroxime krka | Cefuroxime merck | Cefuroxime Panpharma | Cefuroxime qualimed | Cefuroxime Ranbaxy | Cefuroxime Ratiopharm | Cefuroxime Sandoz | Cefuroxime Teva | Cefuroxime Winthrop | Cefuroxime zentiva | Cepazine | Iceca | Zinnat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Britacef | Cefuroxime | Trav cefuroxime | Ximaract | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Enacef | Foxitil | Gebexime | Rocetil | Skycef</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anaptivan | Cefur | Cefuretil | Cefuroprol | Cefuroxime kabi | Ceruxim | Cupax | Feacef | Fredyr | Furaxil | Galemin | Gonif | Interbion | Medoxem | Mosalan | Nelabocin | Nipogalin | Normafenac | Normaphenac | Prokam | Receant | Saxetil | Vekfazolin | Vekfazoline | Yokel | Zetagal | Zilisten | Zinacef | Zinadol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apt Cefuroxime | Axacef | Axim | Ceflour | Cefuroxim stada | Cefuroxime shenzhen | Cefusan | Cmaxid | Farmacef | Furocef | Keroxime | Pulmocef | Quali Cefurnat | Sefuxim | Spizef | Teikeden | Tozef | Vick cefuroxime | Xorimax | Zenatop | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Beloxim | Cefuroksim JGL | Cefuroksim PharmaS | Cefuroxim MIP | Efox | Furocef | Novocef | Novuroxim | Xorimax | Zinnat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cefuroxim Kabi | Cefuroxim MIP | Cefuroxime aptapharma | Ceroxim | Furocef | Ximaract | Xorim | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anbacim | Cefurox | Cefuroxime | Celocid | Cethixim | Kalcef | Kenacef | Naroxit | Oxtercid | Roxbi | Sefure | Sharox | Situroxime | Soxime | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aprok | Ceftal | Cefuroxime | Cefuroxime Actavis | Cefuroxime Teva | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cefurax | Ceroxim | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aaxim | Abactum | Abrocef | Actum | Acvaxim | Addicef | Adexim | Akucef | Altacef | Athxim o | Augxetil | Auroxetil | Axacef | Axeris | Axicef | Axifur | Axotil | Axtl | Bacticure | Bactilem | Barocef | Bigcef | Binex | Bipacef | Britum | C furo | C Rock | C rock 250 | C roxim | C tri t | C-tri | Cebox | Cef bet | Cef-Vepan | Cefac | Ceface | Cefactin | Cefadur ca | Cefakind | Cefam | Cefamax | Cefasyn | Cefax | Cefaxil | Cefbet | Cefblast | Cefdove | Cefialfa | Cefking | Cefo | Cefogen | Cefompy | Cefoprim | Cefoprit | Ceforange A | Ceforim | Cefoxim | Cefrotux | Cefrox | Cefsafe | Ceftalin | Ceftum | Cefuam | Cefucare | Cefuday | Cefuko | Cefulet | Cefuril | Cefurin | Cefuronat | Cefuzact | Cefybond | Cemax Cef | Cemax t | Cerom | Ceroxat | Ceroxim | Ceroxitum | Cetil | Ceurox | Cexum | Clasitil | Clobarium | Coraile | Covatil | CSF | Ct rox | Dericef | Dicef 500 | Dolocef | Ducati 500 | Engel | Entocef | Evercef | Exeption | Exime | Fectiboon | Fervay | Flamicef | Folecef | Forcef | Foroxim | Foru | Foxer | Furix | Furobid | Furocef | Furogen | Furomed | Furonix | Furox | Furoxivio | Garyfix | Genorox | Gericef | Greatum | Happycef | Highcef | Ibcef | Idnaxim | Iviroxime | Joxcy | Kefox | Kefstar | Keroxime | Maxim | Meftem | Megafuro | Mic sef | Milcef | Mixie | Movacef | Neftum axt | Neroxim | Novacef | Novaroxim | Novotil | Ocef | Oltum | Omnixim | Oratil | Pulmocef | Raxim | Refurox | Restum | Riocef | Rockcef | Royalcef | Ruxowel | Sayfur | Seazox | Secrox | Sifurox | Spectraxime | Spizef | Stacey | Stafcure | Supacef | Torfur | Travexel | Twicef | Urox | Viltacef | Warrior | Widecef | Wilcef | X til | Xe | Xeti | Xibid | Xim turbo | Ximoren | Xorimax | Xoxe | Zapisure | Zaxim | Zefu | Zelfix | Zenoxim | Zimetile | Zitacef | Zocef | Zorbicef | Zurocef | Zymocef | Zytum</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Biociclin | Cefamar | Cefoprim | Cefumax | Cefurin | Cefuroxima eg | Cefuroxima Mylan | Cefuroxima sandoz | Cefuroxima teva | Curoxim | Deltacef | Duxima | Itorex | Kefox | Lafurex | Monacef | Oraxim | Tilexim | Ximaract | Zinnat | Zinocep | Zoref</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Cefovex | Ceftal | Cefutil | Cefuzime | Daroxime | Froxime | Gonif | Medo axetine | Nizacef | Oraxim | Supero | U cef | Xorimax | Zamur | Zilisten | Zinacef | Zinaxim | Zinnat | Zinoxime | Zinoximor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Oracef | Zinacef</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Auroxetil | Axacef | Axetine | Bcef | C tri t | Cef2 | Cefact | Cefakind | Cefaks | Cefasyn | Cefaxil | Cefeal | Cefogen | Ceforce | Cefotil | Cefoxim | Cefrim | Cefuaxit | Cefuken | Cefuken ds | Cefuright | Cefurofast | Cefurome | Cefuroxime | Celza | Cerox | Cerox a | Cetil | Ceurox | Cortum | Curox | Dawacef | Evorox | Fetnal | Forcef | Foxitil | Furocef | Furomark | Furotil | Furox | Injroxime | Kefrox | Kefstar | Kefurox | Kilbac | Lebac | Mexirof | Mextil | Milcef | Mydawa cefuroxime | Nelcef | Proximexa | Pulmocef | Rofurox | Roxicef | Rufex | Sanfurox | Sayfur | Sefur | Sefur ds | Spizef | Syner cef | Theoroxime | Ximecor | Xorimax | Zamur | Zinacef | Zinavir ds | Zinaxime | Zinnat | Zocef | Zolidon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Accef | Aju cefuroxime sodium | Alporin | Ausko cefuroxime sodium | Axcef | Bearcef | Binex cefuroxime sodium | Ceactil | Ceatil | Cefactil | Cefrox | Ceft | Ceftil | Cefuking | Cefur m | Cefurosaxime | Cefurotil | Cefuroxil | Cefuroxime | Cefuroxime sodium daewha | Cefuroxime sodium Huons | Cefuroxtil | Cefuroxtin | Cefusime | Cefutil | Cefutin | Cefuxetil | Cefuxil | Celcepoo | Cenet | Cepharoxim | Ceraf | Ceroxim | Cetroc | Cexil | Ckd cefuroxime sodium | Dongkoo cefuroxime sodium | Dongkwang cefuroxime axetil | Epufast | Furaxim | Furaxime | Furoxetil | Furoxim | Glocefuroxime | Gomcef | Hanlim cefuroxime sodium | Hupiroxime | Il yang cefuroxime sodium | Ildong cefuroxime | Jinnetil | Jw cefuroxime | Keroxim | Kyongbo cefuroxim axetil | L furoxime | Newgenpharm cefuroxime | Newroxime | Olcef | Samnam cefuroxime | Samsung cefuroxime sodium | Samxetil | SCD Cefuroxime | Sencef | Seroxin | Shincef | Union cefuroxime sodium | White cefuroxim axetil | Wonfuroxime | Xincet | Zincef | Zincetil | Zinnat | Zinnetil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefovex | Cefutil | Cefuzime | Daroxime | Maxil | Xorim | Zamur | Zenon | Zinacef | Zinnat | Zinoximor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Axacef | Cefaks | Cefora | Cefovex | Cefumax | Cefurex | Cefuroxime | Cefutil | Cefuzime | Daroxime | Maxil | Xorim | Xorimax | Zenon | Zinacef | Zinnat | Zinoximor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Biofuroksym | Cefakind | Cefogen | Cefurox basics | Cefuroxim dr. eberth | Cefuroxim fresenius kabi | Cefuroxime actavis | Cefuroxime ingen pharma | Cefuroxime MIP | Cefuroxin | Intefurox | Ketocef | Refoxim | Ricefan | Supero | Vekfazolin | Ximaract | Xorim | Xorimax | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cefurim | Cefuroxim fresenius | Cefuroxim fresenius kabi | Cefuroxime EG | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Cefasyn | Cefogen | Cefurax | Cefuroxime | Cefuroxime bcpp | Cefuroxime MIP | Elobact | Ketocef | Ricefan | Vekfazolin | Xorimax | Zinacef | Zinadol | Zinnat</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cefutil | Ceroxim | Zinacef | Zinnat | Zinoxime</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cefabiot | Cefagen | Cefantral | Cefuracet | Cefuroxima | Cefuroxima gi kend | Cefuroxima gi leme | Cefuroxima gi pisa | Cefuroxima gi prob | Cefuroxima Ivax | Cefuroxima Senosiain | Cefuroxima sodica | Cetoxil | Froxal | Fucerox | Furobioxin | Lemoxin | Lorbenil | Magnaspor | Nagaxy | Novador | Wayoxima | Ximaken | Zinnat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anikef | Ceflour | Cefuroxime | Cefuroxime axetil zhijun | Ceroxime | Cetil | Cmaxid | Furoxime | Xorimax | Xylid | Zefu | Zilisten | Zinacef | Zinnat | Zocef</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acef | Akkaf cefuroxime axetil | Avrocef | Axacef | Bioessis | Bioxetil | Buroxim | Ceezex | Cefanel xl | Cefsafe | Cefujet | Cefulight | Cefunat | Cefuraxe | Cefuromac | Cefuroxa | Cefuroxime | Ceroxim | Cetil | Chemocef | Clitex | Cuzi cefuroxime | Digicef | Doncinat | Dovxime | Exatil | Furoxetil | Gebexime | Intil | Kezitil | Lexibcure | Licafur | Lifeback cefuroxime | Malven | Miraxim | Olicef | Oxispa | Pemason cefuroxime | Pocco cefuroxime | Pontal cefuroxime | Proximexa | Pulmocef | Qceph | Quincef | Roxicef | Rufex | Sayfur | Sefzitil | Skp cefuroxime | Spizef | Talsure | Tryoxime ds | Upnat | Vaxcel cefuroxime | Xnat | Xymatyl | Zefef | Zinnat</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefofix | Cefuroxim | Cefuroxim hikma | Cefuroximnatrium Sandoz | Ximaract | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefuroxim | Cefuroxim b. braun | Cefuroxim navamedic | Cefuroxim Ratiopharm | Cefuroxim stada | Lifurox | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cefuroxime | Cefuroxime actavis | Cefuroxime AFT | M cefuroxime | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Cefaloxime | Cefstalip | Cefuroxima | Cefusim | Cefuxinil | Ceroxim | Fornax | Fucerox | Furabact | Kilbac | Maxcefur | Ozax | Priobron | Roxime | Supracef | Ximagen | Zinnat | Zocef</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">2 gen | 2 gen scp | Acrocef | Aeroxime | Aeruginox | Alcefur | Alixime | Altacef | Altoxime | Ambifucef | Ambixime | Argixime | Axecrest | Axet | Axetine | Axurocef | Bermucef | Betcef | Biroxil | Cef u | Cefakind | Cefell med | Cefftabs | Cefiject | Cefnat | Cefogen | Cefopti | Cefosan | Cefovex | Cefrone | Cefrox | Cefstal | Ceft | Cefudyne | Cefueast | Cefufarm | Cefuget | Cefumax | Cefumex | Cefupen | Cefupharm | Cefuphil | Cefuplus | Cefura | Cefurax | Cefuremed | Cefurex | Cefurone | Cefurox | Cefuroxime | Cefusaph | Cefustar | Cefuvex | Cefuxcure | Cefuxime | Cefuzime | Cefwin | Cefzime | Cervin | Cesavess | Ceurox | Cevox | Cidokez | Cimex | Clovixime | Cmaxid | Cortum | Cosef | Curecef | Danoxime | Diacefarm | Educef | Efrox | Elixime | Eoroxime | Ephalox | Epirox | Eroxime | Eroxmit | Eurimax | Fetnal | Finax | Floxam | Fumerix | Furocef | Furocem | Furoxy | Gavixime | Gencef | Goxime | Greenxime | Groxime | Groxone | Harox | Hiquacef | Ifurax | Infekor | Irefur | Jectocef | Kabiroxime | Kaftax | Kairoxi | Karixime | Keef 250 | Kefezy | Kefox | Kefstar | Kefsydin | Kefsyn | Kefurox | Kepox | Keroxim | Keunzef | Lasuzef | Laxime | Laxinat | Levexime | Lifurox | Medxil | Medxime | Medzyme | Mefurox | Microzef | Midrox | Mufexime | Myxetil | N xime | Neoxime | Nicocef | Panaxim | Pediacef | Plerozef | Poweroxime | Primuxime | Profurex | Proroxime | Provixime | Proxim | Qualifur | Quiroxef | Raja | Restum | Retacef | Revacef | Rexocare | Rexofen | Rezafil | Rezafil wfi | Robecim | Robisef | Rocef | Rojacef | Romicef | Rovix | Roxicef | Roxime | Roxiprime | Roxxin | Roxym | Rucef | Ruxim | S rox | Secunda | Sharox | Shincef | Sqcef | Sufrexim | Suncetin | Theoroxime | Titacef | Trigenna | Trixime | Trucef | Unoximed | Verile | Vhersef | Viacef | Vispocef | Vitaroxima | Xefu | Xefustal | Ximgencef | Xinatrene | Xorimax | Xyfrox | Zefcid | Zefcure 500 | Zefcure 750 | Zefsur | Zefur | Zefurox | Zefuxim | Zefuxime | Zegen | Zenoxim | Zicef | Zillian | Zinacare | Zinacef | Zinaf | Zinnat | Zocef | Zoltax | Zurenix | Zyrex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Benroxim | Cefogram | Cefril | Ceftin | Cefucef | Cefurox | Cefuzin | Cegrox | Celoxime | Ceroxime | Dowcef | Evorox | Furains | Furoxi | Infrid | Inrox | Kefacef | Kefrox | Kefzy | Keynet | Libroxin | Lute | Miroxim | Mixorec | Obtrude | Optik | Purox | Puroxime | Roxime | Sayfruxime | Sefur | Sefuspore | Seroxin | Supero | Tiracef | Vegarox | Xurox | Zafurox | Zecef | Zinacef | Zinxef | Zocef</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Biocefal | Biofuroksym | Bioracef | Cefox | Cefuroxim Kabi | Cefuroxim MIP | Cefuroxime 1A Pharma | Cefuroxime Ceft Limited | Cefuroxime Genoptim | Cefuroximum 123ratio | Ceroxim | Furocef | Plixym | Tacefur | Tarsime | Ximaract | Xorim | Xorimax | Zamur | Zinacef | Zinnat | Zinoxx</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ceftin | Kefurox | Zinacef</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Antibioxime | Aprokam | Cefuroxima | Cefuroxima actavis | Cefuroxima arrowblue | Cefuroxima basi | Cefuroxima Cinfa | Cefuroxima generis | Cefuroxima hikma | Cefuroxima labesfal | Cefuroxima pharmakern | Cefuroxima sandoz | Cefuroxima teva | Curoxime | Zipos | Zoref</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actocef | Axetie | Cefuroxima dutriec | Cefuroxima guayaki | Cefuroxima heisecke | Cefuroxima lasca | Cerevax | Kesint | Zinnat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Auroxetil | Axetine (IV/IM) | Cefaks | Cefovex | Cefutil | Cefuzime | Daroxime | Maxil | U-Cef | Xorim | Xorimax | Zamur | Zenon | Zinacef | Zinnat | Zinoximor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Axetine | Axycef | Cefuroxima | Cefuroxima aurobindo | Ceroxim | Kefurox | Lifurox | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acenoveriz | Aksosef | Antibioxim | Axetine | Cefroksim j | Cefurabol | Cefuroksim | Cefuroxim | Cefuroxim j | Cefuroxim natrii | Cefuroxime | Cefuroxime kabi | Cefurus | Cefuxime | Cetil | Kefstar | Ketocef | Proxime | Supero | Xorim | Zinacef | Zinnat | Zinoksimor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefofix | Cefovex | Cefrotux | Cefurex | Cefuroxime | Cefutil | Cefuzime | Ceruxim | Daroxime | Emditil | Maxil | U cef | Xorimax | Zamur | Zenon | Zinacef | Zinnat | Zinoxime | Zinoximor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Axacef | Cefuroxim | Cefuroxim fresenius kabi | Cefuroxim norcox | Cefuroxim sandoz | Cefuroxim scand pharm | Cefuroxim stragen | Cefuroxim villerton | Cefuroxime Stravencon | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Axetine | Cefxin | Shincef | Xorimax | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cefuroksim actavis | Cefuroksim alkaloid int | Cefuroksim aptapharm | Ketocef | Novocef | Tvindal | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Axetine | Cefuroxim Kabi | Ceroxim | Furocef | Xelacef | Ximaract | Xorim | Xorimax | Zinacef | Zinnat | Znobact</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Cifarox | Nirox | Sanfurox | Sefzitil | Zinacef</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">C tri t | Cefamar | Cefogen | Ceftil | Cefurim | Cefuroxime | Farmacef | Furoxime | Magnaspor | Neurox | NIKP Cefuroxime | Zinacef | Zinnat | Zocef | Zonef</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aprokam | Cefuroxime | Cefuroxime kabi | U cef | Zifur | Zinnat | Zinox</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aksef | Aprokam | Avifur | Cefaks | Cefatin | Cefeye | Cefrox | Ceftop | Cefurol | Enfexia | Inceptum | Multisef | Oraceftin | Powercef | Sefaktil | Seffur | Sefuroks | Tugens | Zannacef | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Axurocef | Ceflour | Cefoprim | Cefoxin | Cefuroxime | Cefxin | Cekonin | Cfu | Furoxime | Gibicef | Lafurex | Lifurox | Menimycin | Romicef | Ucefaxim | Uroxime | Zinacef | Zinate | Zinnat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abitsef farmyunion | Aksef | Auroxetil | Axetine | Bactilem | Biofuroksym | Biofuroxim | Cefumax | Cefurabol | Cefurox | Cefuroxim | Cefuroxime | Cefutil | Cetil | Enfexia | Euroxim | Furexa | Kimacef | Micrex | Spizef | Yokel | Zinacef | Zinnat | Zocef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Auroxetil | Axetine | Cef2 | Cefakind | Cefrotil | Cefuaxit | Cefuroxime mj | Cefutil | Cefuzime | Celza | Cortum | Kefstar | Proximexa | Pulmocef | Restum | Sanfur | Tryoxim | Tryoxim ds | Zinacef | Zinaxime | Zinnat | Zocef</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Axetie | Cefuroxima | Cefuroxima sandoz | Cefuroxime | Kesint | Roxime | Zinnat | Zinocep</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefuroxima | Seudacin | Xorim | Zencef | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bifumax | Bio dacef | Cecopha | Cefaxil | Cefurimaxx | Cefurofast | Emixorat | Eucinat | Farinceft | Furocap | Glanax | Haginat | Nilibac | Noruxime | Pulracef | Santorix | Spizef | Undtas | Vanmenol | Zaniat | Zanimex | Zinnat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Alkoxime | Auroxime | Betaroxime t | Cefasyn | Cefuaxit | Ceroxim | Cipofix | Curoax | Furocsem | Gulf cefuroxime | Lifurom | Oratil | Pharmacare-cefuroxime | Rolab-cefuroxime | Sandoz cefuroxime | Zefroxe | Zefurime | Zinacef | Zinnat | Zinoxime</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Altacef | Cef | Cefakind | Cefogen | Cefuaxit | Cefurox | Cefuroxime | Cefuxime | Celza | Ceroxim | Cetil | Ceurox | Kefrox | Restum | Sanfurox | Spizef | Uroxime | Zinacef | Zinnat</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ceroxim | Kefloxa 250 | Kefloxa 500 | Zinacef | Zinnat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35763692">
<a name="35763692"></a>Alcobendas Rueda RM, Núñez E, Martín L, et al; Rioped Group. Oral versus intravenous antibiotics for pediatric osteoarticular infection: when and to whom? <i>Pediatr Infect Dis J</i>. 2022;41(9):e351-e357. doi:10.1097/INF.0000000000003619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/35763692/pubmed" id="35763692" target="_blank">35763692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics, "Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months," <i>Pediatrics</i>, 2011, 128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018;132(3):e103-e119. doi: 10.1097/AOG.0000000000002833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799638">
<a name="24799638"></a>Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control Hosp Epidemiol.</i> 2014;35(6):605-627. doi: 10.1086/676022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/24799638/pubmed" id="24799638" target="_blank">24799638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APO-Cefuroxime.1">
<a name="APO-Cefuroxime.1"></a>APO-Cefuroxime (cefuroxime) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10440436">
<a name="10440436"></a>Azimi PH, Barson WJ, Janner D, Swanson R. Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. UNASYN Pediatric Study Group. <i>Pediatr Infect Dis J</i>. 1999;18(7):609-613. doi:10.1097/00006454-199907000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/10440436/pubmed" id="10440436" target="_blank">10440436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2021a">
<a name="Baddour.2021a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2021b">
<a name="Baddour.2021b"></a>Baddour LM, Harper M. Human bites: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bailie.1">
<a name="Bailie.1"></a>Bailie GR, Mason NA. <i>Bailie and Mason’s 2020 Dialysis of Drugs</i>. Saline, MI: Renal Pharmacy Consultants, LLC. 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16044108">
<a name="16044108"></a>Benyamini L, Merlob P, Stahl B, et al, "The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation," <i>Ther Drug Monit</i>, 2005, 27(4):499-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/16044108/pubmed" id="16044108" target="_blank">16044108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg.</i> 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12182257">
<a name="12182257"></a>Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. <i>Clin Ther</i>. 2002;24(7):1134-1147. doi:10.1016/s0149-2918(02)80024-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/12182257/pubmed" id="12182257" target="_blank">12182257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24917580">
<a name="24917580"></a>Carlier M, Noë M, Roberts JA, et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. <i>J Antimicrob Chemother</i>. 2014;69(10):2797-2803. doi:10.1093/jac/dku195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/24917580/pubmed" id="24917580" target="_blank">24917580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ceftin.1">
<a name="Ceftin.1"></a>Ceftin (cefuroxime) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ceftin.2">
<a name="Ceftin.2"></a>Ceftin (cefuroxime) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ceftin.3">
<a name="Ceftin.3"></a>Ceftin (cefuroxime) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Cefuroxime injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Braun.1">
<a name="Braun.1"></a>Cefuroxime Sodium and dextrose (duplex container) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ranbaxy.1">
<a name="Ranbaxy.1"></a>Cefuroxime suspension [prescribing information]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; September 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Cefuroxime tablet [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Cefuroxime tablet [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4047273">
<a name="4047273"></a>Chan MK, Browning AK, Poole CJ, et al. Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. <i>Nephron</i>. 1985;41(2):161-165. doi:10.1159/000183573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/4047273/pubmed" id="4047273" target="_blank">4047273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112. doi: 10.1093/cid/cir1043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis.</i> 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8335516">
<a name="8335516"></a>Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.<i> J Antimicrob Chemother</i>. 1993;31(suppl D):149-158. doi:10.1093/jac/31.suppl_d.149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/8335516/pubmed" id="8335516" target="_blank">8335516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28391404">
<a name="28391404"></a>Dallmann A, Ince I, Solodenko J, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. <i>Clin Pharmacokinet</i>. 2017;56(12):1525-1541. doi: 10.1007/s40262-017-0538-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/28391404/pubmed" id="28391404" target="_blank">28391404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10639354">
<a name="10639354"></a>Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. <i>Antimicrob Agents Chemother.</i> 2000;44(2):304-310. doi:10.1128/aac.44.2.304-310.2000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/10639354/pubmed" id="10639354" target="_blank">10639354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7065695">
<a name="7065695"></a>de Louvois J, Mulhall A, and Hurley R, “Cefuroxime in the Treatment of Neonates,” <i>Arch Dis Child</i>, 1982, 57(1):59-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/7065695/pubmed" id="7065695" target="_blank">7065695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7159072">
<a name="7159072"></a>del Rio Mde L, Chrane DF, Shelton S, McCracken GH Jr, Nelson JD. Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis. <i>Antimicrob Agents Chemother.</i> 1982;22(6):990-994. doi:10.1128/aac.22.6.990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/7159072/pubmed" id="7159072" target="_blank">7159072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10904192">
<a name="10904192"></a>Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. <i>Diagn Microbiol Infect Dis</i>. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/10904192/pubmed" id="10904192" target="_blank">10904192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30777258">
<a name="30777258"></a>Galli L, Venturini E, Bassi A, et al. Common community-acquired bacterial skin and soft-tissue infections in children: an intersociety consensus on impetigo, abscess, and cellulitis treatment. <i>Clin Ther</i>. 2019;41(3):532-551.e17. doi:10.1016/j.clinthera.2019.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/30777258/pubmed" id="30777258" target="_blank">30777258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3878129">
<a name="3878129"></a>Ginsburg CM, McCracken GH Jr, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. <i>Antimicrob Agents Chemother</i>. 1985;28(4):504-507. doi:10.1128/aac.28.4.504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/3878129/pubmed" id="3878129" target="_blank">3878129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20919394">
<a name="20919394"></a>Gower PE, Kennedy MR, Dash CH. The effect of renal failure and dialysis on the pharmacokinetics of cefuroxime. <i>Proc R Soc Med</i>. 1977;70(Suppl 9):151-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20919394/pubmed" id="20919394" target="_blank">20919394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis.</i> 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002709">
<a name="28002709"></a>Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. <i>N Engl J Med</i>. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/28002709/pubmed" id="28002709" target="_blank">28002709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29203481">
<a name="29203481"></a>Hosmann A, Ritscher LC, Burgmann H, et al. Concentrations of cefuroxime in brain tissue of neurointensive care patients. <i>Antimicrob Agents Chemother</i>. 2018;62(2):e02164-17. doi:10.1128/AAC.02164-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/29203481/pubmed" id="29203481" target="_blank">29203481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hu.1">
<a name="Hu.1"></a>Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1416842">
<a name="1416842"></a>Jacobs RF, Brown WD, Chartrand S, et al. Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections. <i>Antimicrob Agents Chemother</i>. 1992;36(8):1614-1618. doi:10.1128/AAC.36.8.1614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/1416842/pubmed" id="1416842" target="_blank">1416842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27494946">
<a name="27494946"></a>Janssen PK, Foudraine NA, Burgers DM, Neef K, le Noble JL. Population pharmacokinetics of cefuroxime in critically ill patients receiving continuous venovenous hemofiltration with regional citrate anticoagulation and a phosphate-containing replacement fluid. <i>Ther Drug Monit</i>. 2016;38(6):699-705. doi:10.1097/FTD.0000000000000330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/27494946/pubmed" id="27494946" target="_blank">27494946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8486575">
<a name="8486575"></a>Konishi K, Suzuki H, Hayashi M, Saruta T. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. <i>J Antimicrob Chemother</i>. 1993;31(3):413-420. doi:10.1093/jac/31.3.413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/8486575/pubmed" id="8486575" target="_blank">8486575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20919391">
<a name="20919391"></a>Kosmidis J, Stathakis C, Anyfantis A, Daikos GK. Cefuroxime in renal insufficiency: therapeutic results in various infections and pharmacokinetics including the effects of dialysis. <i>Proc R Soc Med</i>. 1977;70(Suppl 9):139-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20919391/pubmed" id="20919391" target="_blank">20919391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824827">
<a name="20824827"></a>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. <i>Cochrane Database Syst Rev</i>. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20824827/pubmed" id="20824827" target="_blank">20824827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25800069">
<a name="25800069"></a>Lalic-Popovic M, Paunkovic J, Grujic Z, et al. Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. <i>J Diabetes</i>. 2016;8(2):238-245. doi: 10.1111/1753-0407.12288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/25800069/pubmed" id="25800069" target="_blank">25800069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32211414">
<a name="32211414"></a>Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the Newborn: the need for prospective studies. <i>Front Med (Lausanne)</i>. 2020;7:72. doi:10.3389/fmed.2020.00072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/32211414/pubmed" id="32211414" target="_blank">32211414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860955">
<a name="34860955"></a>Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. <i>J Pharm Technol</i>. 2018;34(2):62-81. doi:10.1177/8755122518755402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/34860955/pubmed" id="34860955" target="_blank">34860955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al, "The Diagnosis and Management of Acute Otitis Media," <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Limb.1">
<a name="Limb.1"></a>Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290233">
<a name="29290233"></a>Lorrot M, Gillet Y, Gras Le Guen C, Launay E, Cohen R, Grimprel E. Antibiotic therapy of bone and joint infections in children: proposals of the French Pediatric Infectious Disease Group. <i>Arch Pediatr</i>. 2017;24(12S):S36-S41. doi:10.1016/S0929-693X(17)30517-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/29290233/pubmed" id="29290233" target="_blank">29290233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876601">
<a name="31876601"></a>Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. <i>Pediatr Infect Dis J</i>. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/31876601/pubmed" id="31876601" target="_blank">31876601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society (SIS) revised guidelines on the management of intra-abdominal Infection. <i>Surg Infect (Larchmt).</i> 2017;18(1):1-76. doi: 10.1089/sur.2016.261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8192458">
<a name="8192458"></a>McLinn SE, Moskal M, Goldfarb J, et al. Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children. <i>Antimicrob Agents Chemother</i>. 1994;38(2):315-318. doi:10.1128/AAC.38.2.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/8192458/pubmed" id="8192458" target="_blank">8192458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Care Excellence (NICE). Sinusitis (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng79. Published October 2017. Accessed January 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21807983">
<a name="21807983"></a>Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. <i>Antimicrob Agents Chemother.</i> 2011;55(10):4619-4630. doi:10.1128/AAC.00182-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/21807983/pubmed" id="21807983" target="_blank">21807983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9017772">
<a name="9017772"></a>Nix DE, Symonds WT, Hyatt JM, et al. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. <i>Pharmacotherapy</i>. 1997;17(1):121-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/9017772/pubmed" id="9017772" target="_blank">9017772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.1">
<a name="Pichichero.1"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17908614">
<a name="17908614"></a>Pichichero ME, Casey JR. Bacterial eradication rates with shortened courses of 2nd- and 3rd-generation cephalosporins versus 10 days of penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. <i>Diagn Microbiol Infect Dis</i>. 2007;59(2):127-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/17908614/pubmed" id="17908614" target="_blank">17908614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428165">
<a name="3428165"></a>Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. <i>Drug Intell Clin Pharm</i>. 1987;21(12):985-989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/3428165/pubmed" id="3428165" target="_blank">3428165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15084807">
<a name="15084807"></a>Scholz H. Streptococcal-A tonsillopharyngitis: a 5-day course of cefuroxime axetil versus a 10-day course of penicillin V. results depending on the children's age. <i>Chemotherapy</i>. 2004;50(1):51-54. doi:10.1159/000077286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/15084807/pubmed" id="15084807" target="_blank">15084807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.1">
<a name="Sethi.1"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23091044">
<a name="23091044"></a>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis</i>. 2012;55(10):1279-1282. doi:10.1093/cid/cis847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23091044/pubmed" id="23091044" target="_blank">23091044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34118486">
<a name="34118486"></a>Siddiqui Z, Tahiri M, Gupta A, Kin Nam RH, Rachmanidou A. The management of paediatric rhinosinusitis. <i>Int J Pediatr Otorhinolaryngol</i>. 2021;147:110786. doi:10.1016/j.ijporl.2021.110786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/34118486/pubmed" id="34118486" target="_blank">34118486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32414479">
<a name="32414479"></a>Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399: Management of tick bites and Lyme disease during pregnancy. <i>J Obstet Gynaecol Can</i>. 2020;42(5):644-653. doi:10.1016/j.jogc.2020.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/32414479/pubmed" id="32414479" target="_blank">32414479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33589366">
<a name="33589366"></a>'t Hoen, LA, Bogaert G, Radmayr C, et al. Update of the EAU/ESPU guidelines on urinary tract infections in children. <i>J Pediatr Urol</i>. 2021;17(2):200-207. doi:10.1016/j.jpurol.2021.01.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/33589366/pubmed" id="33589366" target="_blank">33589366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated September 2, 2022. Accessed January 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Compounding certain beta-lactam products in shortage under Section 503A of the Federal Food, Drug, and Cosmetic Act: Immediately in effect guidance for industry. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic</a>. Published November 2022. Accessed February 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65. doi:10.2165/00148581-200406010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2075076">
<a name="2075076"></a>Vree TB and Hekster YA, "Pharmacokinetics and Tissue Concentrations of Cefuroxime," <i>Pharm Weekbl Sci</i>, 1990, 12(6A):262-6; discussion 267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/2075076/pubmed" id="2075076" target="_blank">2075076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et al; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350458">
<a name="34350458"></a>Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. <i>J Pediatric Infect Dis Soc</i>. 2021;10(8):801-844. doi:10.1093/jpids/piab027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/34350458/pubmed" id="34350458" target="_blank">34350458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23215911">
<a name="23215911"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23215911/pubmed" id="23215911" target="_blank">23215911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23874094">
<a name="23874094"></a>Yoon HI, Lee CH, Kim DK, et al. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.<i> Int J Chron Obstruct Pulmon Dis.</i> 2013;8:329-334. doi: 10.2147/COPD.S41749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23874094/pubmed" id="23874094" target="_blank">23874094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11889273">
<a name="11889273"></a>Yoon PW, Rasmussen SA, Lynberg MC, et al. The national birth defects prevention study. <i>Public Health Rep</i>. 2001;116(Suppl 1):32-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/11889273/pubmed" id="11889273" target="_blank">11889273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zinacef.1">
<a name="Zinacef.1"></a>Zinacef (cefuroxime) [prescribing information]. Buena, NJ: Teligent Pharma, Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zinacef.2">
<a name="Zinacef.2"></a>Zinacef (cefuroxime) [prescribing information]. Buena, NJ: Teligent Pharma, Inc; May 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9230 Version 464.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
